Sentiment Survey
|
|
|
|
|
|
|
|
|
|
|
|
Investment Grade:
|
|
Comments(0)
|
(0)
|
(0)
|
Ranking History
Headlines
- Biovest International Announces Reorganization Plan to Maximize Long-Term Shareholder Value, Fully Pay All Creditors and Continue Operations to Commercialize its Drugs and Technologies
Nov 10, 2008 11:35 AM
- Accentia Biopharmaceuticals Announces Reorganization Plan to Maximize Long-Term Shareholder Value, Fully Pay All Creditors and Continue Operations to Commercialize Its Drug Portfolio
Nov 10, 2008 11:34 AM
- Accentia Biopharmaceuticals Announces Pending Delisting from NASDAQ
Nov 03, 2008 04:24 PM
- Biovest and IDIS Announce Agreement to Launch Named-Patient Program for Anti-Cancer Vaccine in Europe
Oct 29, 2008 09:32 AM
- Accentia Biopharmaceuticals to Present at Rodman & Renshaw 10th Annual Healthcare Conference; Company Also Reports On NASDAQ Compliance Plan
Oct 24, 2008 05:16 PM
- Biovest Announces $1.6M in Federal Funding Appropriated for Groundbreaking Cancer Vaccine & Skin/Bone/Tissue Repair Research
Oct 22, 2008 03:02 PM
- Biovest Announces BiovaxID(R) Anti-Cancer Vaccine Prolongs Cancer-Free Survival by 44%
Oct 07, 2008 11:16 AM
- Accentia Biopharmaceuticals Receives NASDAQ Notice
Sep 26, 2008 05:35 PM
- Accentia Reports Fiscal Third Quarter Financial Results
Aug 14, 2008 05:41 PM
- Biovest Joins in the Formation of the Joint U.S.-Norway Cancer Research Program, a Collaborative Effort with Plans to Present to NCI and the U.S. Military Healthcare System
Aug 05, 2008 09:42 AM
Analyst Ratings
|
|
Share Performance
|
Period
|
ABPI
|
Compare to S&P
|
| YTD |
-94.51 %
|
-89.42 %
|
| 4 Weeks |
-43.75 %
|
-40.08 %
|
| 12 Weeks |
-76.92 %
|
-65.49 %
|
|
Financial Ratios
Earnings Performance
|
EPS Growth in Last Quarter: -25.00 %
|
|
EPS Growth in Last Year: -4.17 %
|
|
Sales Growth in Last Quarter: -28.85 %
|
|
Sales Growth in Last Quarter: -22.11 %
|
|
|
